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Race and Beta-Blocker Survival Benefit in Patients With Heart Failure:
An Investigation of Self-Reported Race and Proportion of African
Genetic Ancestry
Jasmine A. Luzum, PharmD, PhD, BCPS; Edward Peterson, PhD; Jia Li, PhD; Ruicong She, MS; Hongsheng Gui, PhD; Bin Liu, MPH;
John A. Spertus, MD, MPH; Yigal M. Pinto, MD, PhD; L. Keoki Williams, MD, MPH; Hani N. Sabbah, PhD; David E. Lanfear, MD, MS
Background-—It remains unclear whether beta-blockade is similarly effective in black patients with heart failure and reduced
ejection fraction as in white patients, but self-reported race is a complex social construct with both biological and environmental
components. The objective of this study was to compare the reduction in mortality associated with beta-blocker exposure in heart
failure and reduced ejection fraction patients by both self-reported race and by proportion African genetic ancestry.
Methods and Results-—Insured patients with heart failure and reduced ejection fraction (n=1122) were included in a prospective
registry at Henry Ford Health System. This included 575 self-reported blacks (129 deaths, 22%) and 547 self-reported whites (126
deaths, 23%) followed for a median 3.0 years. Beta-blocker exposure (BBexp) was calculated from pharmacy claims, and the
proportion of African genetic ancestry was determined from genome-wide array data. Time-dependent Cox proportional hazards
regression was used to separately test the association of BBexp with all-cause mortality by self-reported race or by proportion of
African genetic ancestry. Both sets of models were evaluated unadjusted and then adjusted for baseline risk factors and beta-
blocker propensity score. BBexp effect estimates were protective and of similar magnitude both by self-reported race and by
African genetic ancestry (adjusted hazard ratio=0.56 in blacks and adjusted hazard ratio=0.48 in whites). The tests for interactions
with BBexp for both self-reported race and for African genetic ancestry were not statistically significant in any model (P>0.1 for all).
Conclusions-—Among black and white patients with heart failure and reduced ejection fraction, reduction in all-cause mortality
associated with BBexp was similar, regardless of self-reported race or proportion African genetic ancestry. ( J Am Heart Assoc.
2018;7:e007956. DOI: 10.1161/JAHA.117.007956.)
Key Words: ancestry • beta-blocker • disparity • genetics • genomics • heart failure • pharmacogenetics
• pharmacogenomics • race
T he landmark clinical trials that established the efficacy ofbeta-blockers in patients with heart failure (HF) with
reduced ejection fraction (HFrEF) predominately consisted of
white patients (80–99%),1–6 despite evidence that black
patients have higher risk for developing and dying from HF.7
Subgroup analyses of these pivotal trials show effect
estimates that are consistent with treatment benefit across
races (though very limited in terms of power),8,9 and
consensus guidelines reasonably recommend beta-blocker
use in all patients with HFrEF unless contraindicated.10 The
extrapolation of clinical trial data from 1 patient race to
another is an important issue because at least 29 medications
(including beta-blockers) are reported to have racial dispar-
ities in safety or efficacy,11 and this is clearly salient in the
setting of HF.12 BEST (Beta Blocker Evaluation of Survival
trial), which tested bucindolol in chronic HFrEF patients,
showed differing effects depending on race with a trend
toward harm among black patients.13,14 Moreover, some
observational data sets have suggested reduced efficacy of
approved beta-blockers in black HFrEF patients.15,16
A complicating issue surrounding race-based analyses is
that race is a subjective social construct associated with a
myriad of demographic, socioeconomic, comorbidity, and
treatment differences that can confound estimates of treat-
ment benefit.17 Moreover, it is imperfectly linked to genetic
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ancestry, which could indicate biological bases for difference
in therapeutic responses, both risks and benefits. There are
significant data suggesting that genetic variation, specifically
many variants that are correlated to ancestral population, may
also impact beta-blocker effectiveness or HF disease
progression.18–21 Unraveling the limitations of these past
reports of racial disparities in beta-blocker efficacy among
HFrEF patients requires genetic ancestry data that can objec-
tively and quantitatively assess ancestral background. It is
particularly important to include genetic ancestry in racial
analyses because self-reported race can substantially disagree
with genetic ancestry, especially in genetically admixed popu-
lations such as in the United States. For example, self-reported
blacks tend to average 20% European genetic ancestry, but
this ranges widely from near zero to majority European genetic
ancestry.11,22 Tohelp evaluate the effectiveness of beta-blocker
use in blacks, as compared with whites, we developed a genetic
HF registry and compared the association between beta-
blocker exposure (BBexp) and risk for all-cause mortality
between self-identified whites and blacks, and then also tested
the beta-blockers’ associations with all-cause mortality by
proportion of African genetic ancestry.
Methods
Patient Data
The study was approved by the Institutional Review Board at
the Henry Ford Health System, and all patients gave written
informed consent before participation. Because of the
sensitive nature of this research, the data, analytical methods,
and study materials will not be made available to other
researchers for purposes of reproducing the results or
replicating the procedure. Patients for this study came from
a prospective genetic registry of HF patients with the overall
goal of discovering novel ways to better predict prognosis and
response to HF treatments. The registry started in October
2007 and completed in March 2015 at the Henry Ford Health
System, which is a vertically integrated health system serving
the primary and specialty healthcare needs of individuals in
southeastern Michigan. The health system includes several
hospitals, a multispecialty physician group of 1200 physi-
cians, as well as an affiliated insurance product (Health
Alliance Plan; all subjects are members). Patients were
included in the HF registry if they were aged ≥18 years,
insured, and met the definition for HF as defined by the
Framingham Heart Study.23 Specifically, patients must have
had at least 2 major, or 1 major and 2 minor, HF criteria
present at the time of exam or documented in the medical
record. Major criteria were paroxysmal nocturnal dyspnea or
orthopnea, neck vein distension, rales, cardiomegaly, acute
pulmonary edema, S3 gallop, increased venous pressure
(16 cm of water), circulation time (≥25 seconds), and hepa-
tojugular reflux. Minor criteria were ankle edema, night cough,
dyspnea on exertion, hepatomegaly, pleural effusion, vital
capacity decreased 33% from maximum, and heart rate
≥120 beats per minute. Weight loss ≥4.5 kg in 5 days in
response to treatment was a major or minor criterion. Patients
were excluded from the registry if they were on dialysis or
dependent on supplemental oxygen or dialysis. Detailed
phenotypic information (eg, demographics, physical examina-
tion, past medical history, laboratory values, functional status,
and medications) and blood samples were collected upon
enrollment into the HF registry. Patient deaths were collected
from the Social Security Administration Death Master File,
Michigan State Division of Vital Records, and the Henry Ford
Health System administrative data, through July 28, 2016. Only
patients with HFrEF were included in this analysis. Patients
with left ventricular ejection fraction (LVEF) <50% verified by
echocardiography, nuclear stress tests, or radionuclide blood
pool imaging were included in the primary analysis (n=1122).
This ejection fraction cutoff was chosen to reflect patients with
systolic HF because the study was designed and started before
the more-recent reclassifications, suggesting that HFrEF
should be defined as an LVEF ≤40%.24 To address whether
this could alter our findings, we performed a secondary
analysis restricted to patients with LVEF ≤40% (n=794).
Calculation of BBexp
BBexp was calculated using dose standardization and phar-
macy claims data as previously described.15 Briefly, doses of
Clinical Perspective
What Is New?
• Previous research suggested racial differences in beta-
blocker effectiveness for treating heart failure with reduced
ejection fraction by self-reported race.
• We re-examined beta-blocker effectiveness by self-reported
race and by genetic ancestry to help distinguish biological
differences by race (ie, the genetic component) from
nonbiological components/correlates of race (eg, diet,
socioeconomic status, and others).
• We found that beta-blocker treatment was associated with a
similar reduction in the risk for mortality in self-identified
blacks compared with whites, regardless of genetic ancestry
(overall proportion African genetic ancestry).
What Are the Clinical Implications?
• This study provides strong reassurance that there is similar
benefit of beta blockade in blacks with heart failure and
reduced ejection fraction compared with white counter-
parts.
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specific beta-blockers were standardized into dose equiva-
lents by the target dose used in clinical trials of HFrEF or, for
beta-blockers not tested in HF clinical trials (eg, atenolol), by
the maximum daily dose. Specifically, these target/maximal
daily doses were 50 mg for carvedilol, 200 mg for metoprolol
(for both long-acting and short-acting formulations), 10 mg
for bisoprolol, 100 mg for atenolol, and 600 mg for labetalol.
For example, 25 mg of carvedilol per day (ie, 12.5 mg twice-
daily) was considered a 0.5 beta-blocker standardized dose
equivalent. Carvedilol (39%) and metoprolol succinate (38%)
were the agents most often used, but there were smaller
groups of patients using metoprolol tartrate (18%) or another
beta-blocker (4%).
BBexp was then calculated by multiplying the standardized
dose equivalent by the quantity of medication dispensed in a
6-month time block, divided by the total number of days in the
6-month time block. BBexp was calculated for each patient for
each day of observation, and thus this method accounts for
both dose and adherence over a rolling period of time
(6 months). For example, if a patient was prescribed 12.5 mg
of carvedilol twice-daily and had picked up their prescription
from the pharmacy so that there was continuous availability
over the previous 6 months, then their calculated BBexp
would be 0.5. We have previously demonstrated that this
approach for calculating BBexp is superior to a single time
point and dichotomous classification of BBexp (eg, discharge
medication status), in terms of correlation to heart rate and
death or hospitalization.25
Genotyping and Genetic Ancestry Analysis
Blood samples were collected at enrollment into the HF
registry and were immediately processed and stored at
70°C. Each sample was genotyped using the Axiom Biobank
array (Affymetrix, Santa Clara, CA), which includes the
following 600K genetic variants: (1) 300K genome-wide
variants with minor allele frequencies >1%; (2) 250K low
frequency (<1%) coding variants from global exome sequenc-
ing projects; and (3) an additional 50K variants to improve
African ancestry coverage (Yoruba in Ibadan, Nigeria [YRI]
booster). The proportion of West African genetic ancestry
(heretofore referred to as African ancestry) in each patient
was estimated using ANCESTRYMAP2.0.26 Briefly, the soft-
ware program uses a Hidden Markov Model to combine data
across unlinked single-nucleotide polymorphisms and incor-
porates information from many neighboring markers to infer
ancestry.
Statistical Analysis
Continuous baseline variables were summarized by the
meanSD and compared by self-reported race with 2-sample
Student t tests. Continuous baseline variables that were not
normally distributed were compared by self-reported race
using the 2-sample Mann–Whitney test. Categorical baseline
variables were summarized by counts and percentages and
compared by self-reported race using v2 tests or Fisher’s
exact tests, when appropriate. Time-dependent Cox propor-
tional hazards regression models were used to assess the
relationship of BBexp with the primary end point of all-cause
mortality. BBexp was modeled as a continuous variable with a
daily value ranging from 0 (pharmacy claims indicated that no
beta-blocker was available to the patient on any day
throughout the 6 months preceding that day) to 1 (pharmacy
claims indicated that target doses of beta-blocker were
available to the patient on every day throughout the 6 months
preceding that day). Because BBexp was modeled as a
continuous variable, the hazard ratios (HRs) for the associ-
ation between BBexp and all-cause mortality were scaled as
zero exposure (0) versus target exposure (1). BBexp was only
dichotomized when plotting survival curves (high exposure
defined as ≥50th percentile and low exposure defined as
<50th percentile). Two separate sets of models were made, 1
for self-identified race (dichotomous variable) and another for
genetic ancestry (continuous variable), that is, both factors
were not in models together. The 2 sets of models were
otherwise similar (ie, same covariates and end points).
Interaction between either self-reported race or proportion
of genetic African ancestry and BBexp was tested by
incorporating a multiplicative interaction term within the
models for time to all-cause mortality (eg, self-identified
race9BBexp). Models stratified by self-identified race were
also developed. The models were adjusted for the Meta-
Analysis Global Group in Chronic Heart Failure (MAGGIC) risk
score27 (excluding beta-blocker as an input variable),
N-terminal pro-b-type natriuretic peptide level, and beta-
blocker propensity score. Beta-blocker propensity score was
calculated using logistic regression of all variables in Table 1
with the output separated into quartiles and used as an
ordinal (1–4) adjuster in the Cox regression models.28 For
main effects, P<0.05 was considered statistically significant,
and for the interaction, P<0.1 was considered statistically
significant. In the analyses stratified by self-reported race, we
estimated 80% power to detect an HR ≤0.65 for beta-blocker
response, which is similar to the reduction in the risk for
mortality reported in the landmark beta-blocker clinical trials.
The primary analysis of African genetic ancestry included
genetic ancestry as a continuous variable, which was available
in all subjects, and thus there was similar power for the
analysis of African genetic ancestry and beta-blocker survival
benefit. However, when race was stratified by African genetic
ancestry <5% and >80%, subjects with African genetic
ancestry between 5% and 80% were excluded (n=27 self-
reported whites and n=165 self-reported blacks excluded).
DOI: 10.1161/JAHA.117.007956 Journal of the American Heart Association 3
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However, the estimated power only decreased slightly when
race was stratified by African genetic ancestry (but not
when African genetic ancestry was used as a continuous
variable) to have 80% power to detect an HR ≤0.63 for
beta-blocker survival benefit. All statistical analyses were
performed in SAS software (version 9.4; SAS Institute Inc,
Cary, NC).
Results
The analytical cohort comprised 1122 HFrEF patients meeting
inclusion criteria: 575 self-reported black patients (51%) and
547 self-reported white patients (49%). The overall group had
a median follow-up of 1089 days (range, 3–3516). There were
a total of 255 deaths in the analysis, 129 among black
patients (22%) and 126 in white patients (23%). Baseline
characteristics overall and stratified by self-reported race are
presented in Table 1. Statistically significant differences at
baseline were present between the groups for many charac-
teristics, including age, sex, ischemic etiology, LVEF, and atrial
fibrillation. Notably, there were no significant differences
between race groups in terms of medication exposure,
specifically including quantified BBexp, categorized BBexp
(none versus any), or categorized angiotensin-converting
enzyme inhibitor or angiotensin receptor blockers. Genetic
admixture was observed in the cohort within both race
groups, but was more prominent in self-identified blacks
(Figure 1). Self-reported whites had an average of 1% African
genetic ancestry, whereas self-reported blacks had an aver-
age of 16% European genetic ancestry.
Table 1. Baseline Characteristics Overall and Stratified by Both Self-Reported Race and Proportion of African Genetic Ancestry
Characteristic
Overall
(n=1122)
Self-Reported Race
P Value*
Proportion of African Genetic
Ancestry
P Value†
Black (n=575)
51%
White (n=547)
49%
>80% (n=410)
37%
<5% (n=520)
46%
Female 394 (35.1%) 231 (40.2%) 163 (29.8%) <0.001‡ 171 (41.7%) 153 (29.4%) <0.001‡
Age, y 67.511.9 64.412.1 70.810.8 <0.001‡ 63.811.8 70.710.8 <0.001‡
LVEF, % 34.711.1 33.411.5 36.110.5 <0.001‡ 32.711.3 36.110.4 <0.001‡
Ischemic etiology 494 (44.0%) 192 (33.4%) 302 (55.2%) <0.001‡ 124 (30.2%) 295 (56.7%) <0.001‡
Hypertension 977 (88.91%) 530 (92.2%) 467 (85.4%) <0.001‡ 383 (93.4%) 442 (85.0%) <0.001‡
Chronic obstructive pulmonary disease 246 (21.9%) 118 (20.5%) 128 (23.4%) 0.244 87 (21.2%) 121 (23.3%) 0.456
Chronic kidney disease 251 (22.4%) 158 (27.5%) 93 (17.0%) <0.001‡ 123 (30.0%) 84 (16.2%) <0.001‡
Atrial fibrillation 311 (27.7%) 113 (19.7%) 198 (36.2%) <0.001‡ 76 (18.5%) 188 (36.2% <0.001‡
Stroke/transient ischemic attack 140 (12.5%) 74 (12.9%) 66 (12.1%) 0.684 53 (12.9%) 60 (11.5%) 0.520
Diabetes mellitus 462 (41.21%) 260 (45.2%) 202 (36.9%) 0.005‡ 189 (46.1%) 193 (37.1%) 0.006‡
Body mass index, kg/m2 31.17.3 31.47.6 30.87.1 0.198 31.37.7 30.87.1 0.301
Systolic blood pressure, mm Hg 12923 131.224.0 126.621.7 0.001‡ 131.724.2 125.921.5 <0.001‡
Heart rate, beats per min 71.213.1 72.313.3 69.912.8 0.002‡ 73.113.6 70.012.4 <0.001‡
NTpro-BNP, pmol/L 358380 353394 364366 0.635 354392 360363 0.812
Serum creatinine, mg/dL 1.280.92 1.381.12 1.180.60 0.001‡ 1.451.27 1.170.61 <0.001‡
MAGGIC risk score (w/o beta-blocker) 17.87.3 17.37.5 18.47.1 0.010‡ 17.47.7 18.47.2 0.045‡
BBexp 26.629.0 26.428.5 26.729.6 0.852 26.029.0 27.036.0 0.626
Any BBexp 781 (76.9%) 401 (76.2%) 380 (77.6%) 0.619 280 (74.7%) 363 (77.7%) 0.298
ACE/ARB exposure 616 (54.9%) 331 (57.6%) 285 (52.1%) 0.066 238 (58.1%) 272 (52.3%) 0.081
Proportion African genetic ancestry 43.444.0 83.520.4 1.06.6 <0.001‡ NA NA NA
Length of follow-up, d 1089699 1082695 1097703 0.737 1090708 1109708 0.699
Deaths 255 (22.7%) 129 (22.4%) 126 (23.0%) 0.811 92 (22.4%) 115 (22.1) 0.906
ACE indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BBexp, beta-blocker exposure; LVEF, left ventricular ejection fraction; MAGGIC, Meta-Analysis
Global Group in Chronic Heart Failure risk score27; NA, not applicable; NTpro-BNP, N-terminal pro-b-type natriuretic peptide.
*P value for self-reported black vs white.
†
P value for >80% African genetic ancestry vs <5% African genetic ancestry.
‡
P<0.05.
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Overall, the quantified beta-blocker exposure metric
(BBexp) varied from 0% to 100% across the cohort and over
time. Figure 2 depicts the mean BBexp for each individual
from least to most across the cohort. Roughly 25% of patients
had no BBexp, whereas 55% had intermediate levels of BBexp
and 20% had relatively high-intensity BBexp. In the overall
cohort, BBexp was associated with improved survival. Unad-
justed analysis revealed BBexp HR of 0.47 (P=0.001). When
adjusted for baseline Meta-Analysis Global Group in Chronic
Heart Failure (MAGGIC) score (without the beta-blocker
variable input), N-terminal pro-b-type natriuretic peptide, and
self-reported race (race is not a component of MAGGIC) the
BBexp continued to be strongly protective with an adjusted
HR (aHR) of 0.49 (P=0.005).
Beta-Blocker Association With Time to Death by
Self-Identified Race and Genetic Ancestry
We tested Cox models of BBexp on the time to death in
univariable analysis and then analyses adjusted for baseline
MAGGIC score (minus beta-blocker input). In unadjusted
analyses stratified by race, BBexp was strongly protective in
both groups, though showing some numeric separation.
Among white patients, BBexp HR was 0.41 (95% confidence
interval, 0.22, 0.76; P=0.005), whereas in black patients the
HR was 0.55 (95% confidence interval, 0.31, 0.98; P=0.041).
Once adjusted for baseline risk using MAGGIC score alone,
the HRs in each group were more closely aligned. For whites,
the BBexp aHR was 0.45 (0.24, 0.86; P=0.016), whereas for
Figure 1. Proportion of African genetic ancestry in the self-reported whites (left panel) and blacks (right panel). YRI indicates Yoruba in Ibadan,
Nigeria.
Figure 2. Mean beta-blocker exposure metric (BBexp, Y axis) for each participant across the
cohort (X axis).
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black patients the aHR was 0.54 (0.30, 0.97; P=0.038), again
statistically significant in both groups. Formal testing for the
interaction of race with BBexp (ie, adding race9BBexp term in
the model) was also not significant (b=0.17; P=0.70). The
relationship of BBexp to survival, stratified by race, is
presented in Table 2 and illustrated in Figure 3.
We then sought to examine whether genetic ancestry, a
better reflection of genetic differences across race (rather than
self-identified race), modulated the association of BBexp with
survival times. Specifically, we estimated proportion of African
ancestry for each individual and then tested similar time-
dependent Cox models as above, but with proportion of African
genetic ancestry included as a numerical covariate and with
interaction terms. The BBexp effect did not appear to differ
across the spectrum of African genetic ancestry. In models
including BBexp, MAGGIC, and proportion African genetic
ancestry, genetic ancestry was not statistically significant
(P=0.77), and the BBexp effect estimate was similar to the
above (aHR=0.50; P=0.002). Formal testing with interaction
term (BBexp9ancestry) was also not statistically significant
(P=0.71). To better illustrate this lack of impact of African
genetic ancestry on beta-blocker effectiveness, if the BBexp HR
is tabulated using a proportion African genetic ancestry of <5%
versus >80%, the unadjusted HR generated are 0.70 and 0.72,
respectively. A comparison of HRs for high versus low BBexp in
each race category is presented in Table 3.
Sensitivity Analyses
We performed several secondary analyses to assess whether
our results were impacted by certain potential confounders or
classification schemes. First, because this was an observa-
tional study, confounding by indication or disease severity is
always a concern. The primary analysis plan included
adjustment for baseline risk by using a validated clinical risk
score (MAGGIC). To supplement this, we additionally tested
models adjusted for baseline N-terminal pro-b-type natriuretic
peptide levels and propensity for beta-blocker use. In terms of
overall beta-blocker effect, when including propensity as the
only covariate, the BBexp effect remains very consistent with
the unadjusted overall analysis (aHR of 0.50; P=0.002). The
results were also similar in models adjusted for MAGGIC, race,
N-terminal pro-b-type natriuretic peptide, and propensity
(Table 2). Importantly, in the full model, the race9BBexp
interaction remains insignificant (b=0.21; P=0.64), race was
not a significant predictor of outcome, and in the race-
stratified models the BBexp aHR were relatively similar (BBexp
aHR 0.48 for whites and 0.56 blacks), with the estimates for
each race group indicating a strong protective association.
To address potential concerns regarding the fact that
ejection fraction <50% was part of the inclusion criteria (as
opposed to ≤40%), we performed additional analyses Ta
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restricted to those patients with LVEF ≤40%. Among the 1122
total subjects, 794 had ejection fraction ≤40% (n=370 white
patients and n=424 black patients). In these subgroups, the
BBexp HR was 0.58 (P=0.14) and 0.59 (P=0.09) for whites
and blacks, respectively. In the full model of all patients with
ejection fraction ≤40% (n=717) adjusted for MAGGIC, race,
and race9BBexp interaction, the BBexp HR was 0.61 (0.38,
0.98; P=0.040) and the interaction was not significant
(P=0.78).
Discussion
Definitive evidence for the efficacy of beta-blockers in blacks
with HFrEF will likely never be obtained given that the pivotal
trials did not include a sufficient number of such participants
and further randomized trials would likely be deemed
unethical. Whereas the preponderance of evidence suggests
a strong benefit, this prospective, observational study extends
past studies by both using self-reported race as a potential
marker of a cluster of factors that differ and genetic ancestry
as a quantifiable and objective biological construct. For
example, if we had found a significant difference in beta-
blocker response by self-reported race and not genetic
ancestry, then that could have suggested that the difference
is likely attributed to sociocultural differences rather than
biological. The fact that we found similar reductions in
mortality stratified by self-reported race (representative of
biological+sociocultural effects) and genetic ancestry (repre-
sentative of only biological effects) is reassuring that beta-
Figure 3. Survival curves stratified by self-reported race and high vs low beta-blocker (BB) exposure. High
beta-blocker exposure was defined as ≥50th percentile (dashed lines) and low beta-blocker exposure as
<50th percentile (solid lines). Red lines are self-reported blacks and blue lines are self-reported whites.
Table 3. HRs and 95% CIs for High Beta-Blocker Exposure (≥50th Percentile) versus Low Beta-Blocker Exposure (<50th Percentile)
in the Self-Reported Races and Patients With <5% and >80% Proportion African Genetic Ancestry
BBexp
Race Category
Self-Report Genetic
White Black <5% African >80% African
High vs low n=516
0.74 (0.52–1.06)
P=0.102
n=543
0.69 (0.49–0.99)
P=0.045*
n=490
0.71 (0.49–1.03)
P=0.071
n=388
0.64 (0.42–0.98)
P=0.038*
Interaction P value P=0.979 P=0.992
All models were adjusted for MAGGIC risk score (minus beta-blocker) and NTpro-BNP level, and the sample sizes were for patients with complete data available for analysis. BBexp
indicates beta-blocker exposure; CI, confidence interval; HR, hazard ratio; MAGGIC, Meta-Analysis Global Group in Chronic Heart Failure risk score27; NTpro-BNP, N-terminal pro-b-type
natriuretic peptide.
*indicates P < 0.05.
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blockers are equally effective in white and black patients. We
found a marked reduction in mortality associated with beta-
blocker treatment that was similar in blacks and whites,
regardless of race or genetic ancestry. Compared with the
landmark trials for HF-approved beta-blockers, our study
includes roughly the same number of black patients (n=575)
as the number of black patients in the MERIT-HF (Metoprolol
CR/XL Randomised Intervention Trial in Congestive Heart
Failure), US Carvedilol Trial, COPERNICUS (Carvedilol
Prospective Randomized Cumulative Survival Trial), and
CIBIS-II (second Cardiac Insufficiency Bisoprolol Study) com-
bined (n=546). The BEST trial of the non–US Food and Drug
Administration–approved bucindolol included 627 black
patients, but treatment with bucindolol trended toward
increased all-cause mortality in the black patients and a
significant test for interaction of treatment benefit with
patient race, further supporting the importance of this race-
stratified analysis. This study is the first to examine this issue
by quantified genetic ancestry, which can potentially offer a
more-granular view of the biological portion of race. Previous
studies on the genetic differences in beta-blocker response
have relied on candidate gene approaches, particularly
candidate polymorphisms affecting adrenergic activity.29
Adverse genetic polymorphisms in the adrenergic system
that are associated with decreased beta-blocker response are
most frequent in blacks. The strength of our approach using
whole-genome ancestry informative markers is that it cap-
tures ancestral variation across the entire genome, and it
accounts for population substructure, a well-known phe-
nomenon that confounds genetic association studies.30
Our data provide additional insight in the context of past
literature. Our findings are similar to previous observational
studies investigating racial differences in beta-blocker
response in HF patients,16 which found protective, though
nonsignificant, HRs for mortality, similar to the clinical trial
data for carvedilol and metroprolol succinate in blacks. Our
data show a significant benefit in blacks, and add a major
advantage compared with previous observational studies, in
that we utilized time-dependent quantified BBexp calculated
from pharmacy claims. This method is a far more-granular and
sensitive way of quantifying drug exposure (accounts for
adherence, dose variability, and changes over time) compared
with dichotomized baseline classification schemes, which
were usually used in the previous studies. Our data do
contrast with the BEST trial findings, as well as our previous
retrospective study,15 which yielded a statistically significant
race interaction for beta-blocker–associated benefit (ie,
increased beta-blocker benefit in whites compared with
blacks for the composite end point of all-cause mortality
plus hospitalization). Given the totality of data, the BEST
findings seem most easily explained as an agent-specific
effect, given that several studies with the other beta-blocking
agents concur with our current observations.31,32 The
contrast with our previous data is most likely attributed to
differences in the end point used. Our previous work utilized a
composite end point including hospitalization, and indeed
when examining our previous data, the differences between
racial groups were driven primarily by hospitalization.15 All-
cause mortality alone (used in this prospective study) may be
a better end point than the composite end point of all-cause
mortality+hospitalization (used in our previous, retrospective
study) for evaluating beta-blocker efficacy. Hospitalization of
HF patients is influenced by factors that are unrelated to beta-
blocker efficacy more than all-cause mortality, such as patient
refusal, lack of available beds, the number of cardiologists,
whether the patient came to the hospital from home or a
skilled nursing facility, and even the day of the week.33–36
Ultimately, hospitalization is the discretion of the treating
physician in the emergency room or clinic. Beta-blockers
decreased the risk of hospitalization in the landmark clinical
trials, but as noted previously, the enrollment of blacks in the
landmark clinical trials was extremely low. Recent data show
that hospitalization rates significantly differ by race,34 and
thus inclusion of hospitalization in the end point may
confound the results in race-stratified analyses such as this
study.
An additional strength of this study was the inclusion of
genetic ancestry to explore more biologically based mecha-
nisms of potential racial differences in beta-blocker effective-
ness. This is an important consideration because of the
known and significant genetic admixture in the United
States,17 as well as the complexity of self-identified race as
a social construct. The availability of genetic ancestry can
help differentiate true inherited differences versus the wide
range of environmental factors that are associated with self-
identified race, such as socioeconomic status, diet, and
healthcare quality and accessibility, all of which can make
attempts to understand the underlying cause of race dispar-
ities in health outcomes very difficult.37 It is important to
interrogate the role of genetic ancestry because socioeco-
nomic factors do not fully explain the critical race disparities
in HF outcomes,38 and to try to quantify potential genetic and
biological effects. For example, African genetic ancestry is
associated with poorer diastolic function parameters in HF
patients.39 Consistent with the literature, substantial genetic
admixture was observed in our patient population, and despite
the potential for differences in outcomes in self-reported race
versus genetically defined ancestry, the reduction in the risk
for mortality from beta-blockers in our study was mostly
similar across the entire spectrum. The fact that even
quantified African genetic ancestry proportion, a granular
marker of genetic race, was also not associated with
differences in beta-blocker benefit provides some additional
reassurance of equal effectiveness in blacks.
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Limitations
Our study should be interpreted in the context of the following
potential limitations. Whereas an observational study can never
definitively assess absolute efficacy such as in a clinical trial, we
have taken great care to adjust for potential confounders. We
sought to mitigate confounders inherent in observational study
design by adjusting with several methods, including a compre-
hensive and previously validated clinical score, a biomarker,
and a beta-blocker propensity score. Supporting our external
validity is that the beta-blocker benefit estimates were similar
to those expected from clinical trials, and overall were
statistically significant. Another limitation of our study was
that beta-blockers approved specifically for HF (ie, carvedilol,
metoprolol succinate, and bisoprolol) were not distinguished
from other beta-blockers. However, of the patients who were
taking beta-blockers at baseline, the vast majority (78%) were
taking HF-approved agents; the most frequent nonapproved
agent being metoprolol tartrate (18%), and only 4% of patients
taking some other beta-blocker. Despite inclusion of other
beta-blockers and low beta-blocker treatment rate, an advan-
tage of this observational study design is that it more closely
represents current, real-world clinical practice than the older
randomized controlled trials. Moreover, a range of beta-blocker
treatment (from zero, to low, to target exposure) allows analysis
of beta-blocker benefit, which would not be possible if all
patients were treated with target doses of beta-blockers. Even
with inclusion of other beta-blockers, our results are reassuring
given that overall the beta-blocker survival benefit was
statistically significant in both groups and of a magnitude
which approximates the findings from randomized trials of
approved beta-blocking agents. Finally, our data are from
insured patients in a single health system, so although our
service population is diverse and reflects the greater regional
population,40 the fact that all patients had insurance and
access to care may somewhat limit the generalizability.
Conclusions
Our prospective, observational study demonstrates that beta-
blocker–associated reduction in the risk for mortality in HFrEF
patients is similar between self-reported black race and
genetically assigned African race, as compared with whites.
We further demonstrate that the overall proportion of African
genetic ancestry, defined by genome-wide ancestry informa-
tive markers, does not modify the beta-blocker benefit. These
data lend further credence to current guidelines that recom-
mend beta-blocker use in all HFrEF patients, reassuring
patients and providers that black HFrEF patients are likely
deriving similar benefit from beta-blocker treatment. These
findings are not suggestive of genetic mechanisms meaning-
fully impacting beta-blocker effectiveness relative to race.
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